Midodrine Titration Protocol for Orthostatic Hypotension
Start midodrine at 2.5-5 mg three times daily and titrate upward by 2.5 mg increments at weekly intervals to a maximum of 10 mg three times daily, with the last dose administered no later than 6 PM to avoid supine hypertension. 1
Starting Dose and Initial Administration
Begin with 2.5-5 mg three times daily in most patients. The FDA label indicates that clinical trials used starting doses in this range, with systematic upward titration based on response 2. For patients with severe symptoms or those who have previously responded to midodrine, you may consider starting at 5 mg three times daily 3.
Critical timing consideration: Administer the last dose before 6 PM to minimize the risk of nocturnal supine hypertension, as the drug's pressor effects persist for 2-4 hours after dosing 2.
Titration Strategy
Weekly dose escalation is the evidence-based approach:
- Increase by 2.5 mg increments at each step
- Titrate at weekly intervals until symptomatic improvement or maximum dose reached
- Target dose range: 5-10 mg three times daily 1
- Maximum recommended dose: 10 mg three times daily (30 mg total daily dose) 4, 5
The dose-response relationship is linear—higher doses produce greater blood pressure increases, with 10 mg typically raising standing systolic BP by 15-30 mmHg at 1 hour post-dose 2, 3, 5. However, doses above 10 mg three times daily substantially increase the risk of supine hypertension (45% at 20 mg vs 22% at 10 mg) without proportional symptom benefit 2.
Monitoring During Titration
Measure blood pressure in three positions at each titration visit:
- Supine BP (after 5 minutes rest)
- Sitting BP
- Standing BP at 1 and 3 minutes (peak effect occurs at 1 hour post-dose)
Schedule BP measurements approximately 1 hour after midodrine administration to capture peak effect 2, 5. The therapeutic goal is to increase standing systolic BP by 15-30 mmHg while keeping supine systolic BP below 180 mmHg 6, 2.
Assess symptom improvement using specific metrics:
- Dizziness/lightheadedness severity
- Syncope frequency
- Ability to perform daily activities
- Standing time tolerance
Dose Adjustment Based on Response
If inadequate response at 1 week: Increase by 2.5 mg per dose (7.5 mg total daily increase)
If supine hypertension develops (systolic >180 mmHg):
- Reduce dose by 2.5 mg per administration
- Consider eliminating the evening dose first
- Elevate head of bed 10 degrees at night 1
If symptoms resolve: Continue current dose without further escalation. The goal is the minimum effective dose that controls symptoms 7, 8.
Common Pitfalls and Safety Monitoring
Supine hypertension is the most significant dose-limiting adverse effect, occurring in 8-22% of patients at therapeutic doses 3, 2. This risk necessitates:
- Strict adherence to the "no dosing after 6 PM" rule
- Head-up tilt sleeping (10 degrees)
- Regular supine BP monitoring
Other adverse effects to monitor:
- Scalp tingling/piloerection (13.5% of patients)—usually mild and self-limited 3
- Urinary retention (4%)—particularly concerning in elderly men with prostatic hypertrophy 6
- Bradycardia—reported in up to 46% in some series, though rarely requires discontinuation 9
Contraindications to continued titration:
- Persistent supine systolic BP >200 mmHg
- Symptomatic supine hypertension
- Urinary retention requiring intervention
- Lack of symptomatic improvement after reaching 10 mg three times daily
Duration of Action and Dosing Frequency
The active metabolite (desglymidodrine) has a half-life of 3-4 hours, with blood pressure effects lasting 2-4 hours 2, 5. This pharmacokinetic profile supports three-times-daily dosing rather than more frequent administration. Some patients may benefit from dosing only when upright activities are planned rather than fixed three-times-daily scheduling 7.
When to Stop Titration
Discontinue midodrine if:
- No significant symptomatic improvement after 3-4 weeks at maximum tolerated dose 2
- Intolerable adverse effects develop
- Supine hypertension cannot be managed with dose reduction and positional measures
The FDA approval was based on surrogate endpoints (standing BP increase), and the label explicitly states that treatment should continue only in patients reporting significant symptomatic improvement 2.